I can't speak to Sanofi's risk calculus, but the pharma did say the deal allows it “to offer increased physician and patient choice in RSV and hMPV by adding a non-mRNA vaccine to its pipeline.”
I can't speak to Sanofi's risk calculus, but the pharma did say the deal allows it “to offer increased physician and patient choice in RSV and hMPV by adding a non-mRNA vaccine to its pipeline.”